Wilmington Savings Fund Society, FSB 13F: Cuts LLY Stake by $3M

Wilmington Savings Fund Society reduced its holdings in Eli Lilly and Company LLY by 2,600 shares during the third quarter, according to a Form 13F filing on October 23, 2026. The institutional investor disclosed a final stake of 25,292 shares valued at $29,264,867, marking a 9.3% decrease from the previous quarter when it held 27,892 shares.

LLY Eli Lilly and Company

$1,273.46 ▲ +18.44% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Wilmington Savings Fund Society's Eli Lilly Position

The filing shows that the firm pared back its investment by 9.32% during the period. The remaining block of 25,292 shares sat at a reported value of nearly $29.3 million as of the filing date.

Other Institutional Activity in Eli Lilly

Other large investors adjusted their positions in Eli Lilly around the same time. True North Advisors grew its holdings by 1,108 shares to 4,217 shares worth about $4,879,120, a 35.6% increase. Symphony Financial lifted its stake by 1,205 shares, ending with 7,802 shares valued at approximately $9,191,438. Strategic Blueprint cut its holdings by 785 shares to 12,911 shares worth about $14,938,745. Lilly Endowment, Inc trimmed its huge position by 307,272 shares, leaving it with 90,066,78 shares valued at roughly $114,696,690,285. PNC Financial Services Group, Inc. lowered its stake by 5,133 shares to 51,322,720 shares worth about $65,357,429,006.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly shares closed at $1,273.46 on the filing date of October 23, 2026, and recently traded around $1,273.57 on October 24, 2026. The stock trades above its 50-day moving average of $1,185.32 and sits well above its 200-day moving average of $1,084.11. The share price is roughly 3.6% below its 52-week high of $1,321.21 and about 58.0% above its 52-week low of $806.02.

Recent Earnings

Eli Lilly posted trailing-twelve-month revenue of $79,666,003,968 alongside earnings of $29.79 per share. The healthcare company reported a year-over-year revenue growth rate of 47.7% and a net profit margin of 33.5%. The company's next earnings report is scheduled for release on October 29, 2026.

Dividend

Eli Lilly distributes an annual dividend rate of $6.92 per share, which translates to a dividend yield of 0.53%. The payout ratio stands at 21.7%, meaning the company uses about a fifth of its earnings to cover dividend payments to shareholders.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several sales prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total of $5,950,000. Officer Donald A Zakrowski disposed of 2,000 shares on August 10, 2026, at $1,185.01 per share totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share for a total value of $7,638,150.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. JP Morgan maintained an Overweight rating while lifting its target to $1,500.00 on September 28, 2026. Morgan Stanley kept an Overweight rating and raised its target to $1,430.00 on October 7, 2026. Cantor Fitzgerald maintained an Overweight rating with a $1,440.00 target on October 8, 2026. RBC Capital reiterated an Outperform rating with a $1,500.00 target on October 12, 2026. Leerink Partners kept an Outperform rating and moved its target to $1,316.00 on October 21, 2026. The stock carries a consensus buy recommendation from 30 analysts, with a mean price target of $1,331.55.

About Eli Lilly and Company

Eli Lilly and Company is a large healthcare firm based in Indianapolis, Indiana. The company focuses on discovering, developing, and manufacturing pharmaceutical treatments for human health across global markets, including metabolic disorders, oncology, and immunology.

Bottom Line

Investors will look to the upcoming earnings release on October 29, 2026, for fresh updates on revenue growth and drug demand. Future Form 13F filings will show whether institutional managers continue to adjust their holdings in the healthcare giant.